ZAI LAB LIMITED Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
ZAI LAB LIMITED (ZLAB) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2025-11-06
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2025-09-30 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2025-06-30 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2025-03-31 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for the quarter ending 2024-09-30 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2021 was $0.00.
- ZAI LAB LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2020 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 3 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 6 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 9 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $0.00 derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-K · filed 2024-02-27 | |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-02-27 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2020-06-30 | $0.00 6-K · filed 2020-09-11 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $0.00 6-K · filed 2020-01-21 | ||
| 2019-06-30 | $0.00 6-K · filed 2020-09-11 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-03-01 | |||
| 2017-12-31 | $0.00 20-F · filed 2020-04-29 | |||
| 2016-12-31 | $0.00 20-F · filed 2019-03-29 | |||
| 2015-12-31 | $0.00 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |